Clinical trial
A Study of the Safety and Efficacy of Infliximab(REMICADE) in Pediatric…
NCT00336492 · Centocor, Inc., Industry · Completed
Key facts
| NCT number | NCT00336492 |
|---|---|
| Title | A Study of the Safety and Efficacy of Infliximab(REMICADE ) in Pediatric Patients With Moderately to SeverelyActive Ulcerative Colitis |
| Official title | A Phase 3, Randomized, Open-label, Parallel-group, Multicenter Trial to Evaluate the Safety and Efficacy of Infliximab (REMICADE) in Pediatric Subjects With Moderately to Severely Active Ulcerative Colitis |
| Lead sponsor | Centocor, Inc., Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Ulcerative Colitis |
| Intervention type | Biological |
| Interventions | infliximab |
| Enrollment | 60 |
| Start date | Sep 1, 2006 |
| Primary completion | May 1, 2009 |
| Completion | Apr 1, 2010 |
| First posted | Jun 13, 2006 |
| Last update posted | Jul 30, 2013 |
| Countries | Belgium, Canada, Denmark, Netherlands, United States |
At a glance
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: